” We have excellent opportunities before us, and we remain focused on delivering patient, company and shareholder value,” said
October –
- The Group's net sales amounted to
SEK 0 (0) thousand. - Operating expenses amounted to
SEK 91,062 (30,523) thousand, an increase of 198%. - The Group's loss after tax amounted to
SEK 90,543 (30,477) thousand. - The Group's earnings per share before and after dilution amounted to
SEK -2.58 (-1.06). - Cash flow from operating activities amounted to
SEK -20,395 (-22,306) thousand. - Cash flow from financing activities amounted to
SEK 54,561 (76,025) thousand. - Cash flow for the period amounted to
SEK 34,166 (53,747) thousand. - Cash and cash equivalents at the end of the period amounted to
SEK 62,395 (108,245) thousand.
January –
- The Group's net sales amounted to
SEK 0 (0) thousand. - Operating expenses amounted to
SEK 224,496 (105,705) thousand, an increase of 112%, driven primarily by the two clinical studies in RA and higher administrative costs caused by the acquisition of TXP and write down of goodwill. - The Group's loss after tax amounted to
SEK 215,810 (99,205) thousand. - The Group's earnings per share before and after dilution amounted to
SEK -6.64 (-3.60). - Cash flow from operating activities amounted to
SEK -100,177 (-117,555) thousand. - Cash flow from financing activities amounted to
SEK 53,984 (200,712) thousand. - Cash flow for the period amounted to
SEK -45,823 (83,184) thousand
Significant events during the period
Oct 3 - SynAct announces additional data from the EXPAND P2b clinical trial further supporting efficacy and activity seen in patients with elevated CRP.Oct 11 - SynAct carries out a directed issue of shares and warrants raising initial gross proceeds ofSEK 60.5 million .Oct 12 - SynAct publishes prospectus in connection with admission to trading of new shares on Nasdaq Stockholm.Oct 31 - Change in number of shares and votes in SynAct Pharma. As ofOctober 31, 2023 , the total number of shares and votes inSynAct Pharma AB amounts to 35,570,980.Nov 1 - SynAct announces evaluation of the 4-week RESOLVE P2a clinical trial in moderate to severely active rheumatoid arthritis patients with an incomplete response to methotrexate.
Significant events after the end of the period
Jan 28 - The Board of Directors ofSynAct Pharma AB has- received a request to convene an EGM
Jan 30 - SynAct expands itsRheumatology Clinical Advisory Board with three new highly experienced advisors.Feb 1 - SynAct appointsKirsten Harting as Chief Medical Officer.Feb 7 - Notice of extraordinary general meeting inSynAct Pharma AB . Upon request by >10% of the shareholders, an extra general meeting has been set toMarch 20, 2024 .Feb. 22 - SynAct announces additional data from the EXPAND P2b clinical trial supporting continued development of the compound in rheumatoid arthritis.
For further information about SynAct Pharma AB, please contact:
CEO,
Phone: +46 727 44 41 58
Email: TBJE@synactpharma.com
Email: investor.relations@synactpharma.com
CFO, SynAct Pharma AB
Phone: +46 703 33 91 23
Email: BWE@synactpharma.com
© Modular Finance, source